Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The mammalian target of rapamycin (mTOR)/p70 S6 kinase 1 (S6K1) pathway is a critical signaling component in the development of obesity-linked insulin resistance and operates a nutrient-sensing negative feedback loop toward the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt pathway. Whereas acute treatment of insulin target cells with the mTOR complex 1 (mTORC1) inhibitor rapamycin prevents nutrient-induced insulin resistance, the chronic effect of rapamycin on insulin sensitivity and glucose metabolism in vivo remains elusive. RESEARCH DESIGN AND METHODS: To assess the metabolic effects of chronic inhibition of the mTORC1/S6K1 pathway, rats were treated with rapamycin (2 mg/kg/day) or vehicle for 15 days before metabolic phenotyping. RESULTS: Chronic rapamycin treatment reduced adiposity and fat cell number, which was associated with a coordinated downregulation of genes involved in both lipid uptake and output. Rapamycin treatment also promoted insulin resistance, severe glucose intolerance, and increased gluconeogenesis. The latter was associated with elevated expression of hepatic gluconeogenic master genes, PEPCK and G6Pase, and increased expression of the transcriptional coactivator peroxisome proliferator–activated receptor-γ coactivator-1α (PGC-1α) as well as enhanced nuclear recruitment of FoxO1, CRTC2, and CREB. These changes were observed despite normal activation of the insulin receptor substrate/PI 3-kinase/Akt axis in liver of rapamycin-treated rats, as expected from the blockade of the mTORC1/S6K1 negative feedback loop. CONCLUSIONS: These findings unravel a novel mechanism by which mTORC1/S6K1 controls gluconeogenesis through modulation of several key transcriptional factors. The robust induction of the gluconeogenic program in liver of rapamycin-treated rats underlies the development of severe glucose intolerance even in the face of preserved hepatic insulin signaling to Akt and despite a modest reduction in adiposity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Specifically, compensatory pathways are activated in response to chronic rapamycin treatment [66, 67].”
From AMPK hyperactivation promotes dendrite retraction, synaptic loss, and neuronal dysfunction in glaucoma (2021) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787 · cited 3×
“Diabetes 59:1338–1348, 2010 The mammalian target of rapamycin (mTOR) is a Ser/Thr kinase that belongs to the phosphatidylinositol (PI) kinase-related protein kinase family (1).”
BackgroundWatterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1
Yoon, J. C., Puigserver, P., Chen, G., Donovan, J., Wu, Z., Rhee, J., Adelmant, G., Stafford, J., Kahn, C. R., Granner, D. K., et al. (2001) · Nature · doi:10.1038/35093050 · Cited by 1,821 · cited 1×
“We also found that rapamycin markedly increases PGC-1 mRNA expression, which likely contributes to the upregulation of the gluconeogenic enzymes, as observed in type 2 diabetes (32).”
BackgroundAbsence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex
Cunningham, J. T., Rodgers, J. T., Arlow, D. H., Vazquez, F., Mootha, V. K., & Puigserver, P. (2007) · Nature · doi:10.1038/nature06322 · Cited by 1,488
Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003) · Nature · doi:10.1038/nature01667 · Cited by 1,487
CREB regulates hepatic gluconeogenesis through the coactivator PGC-1
Herzig, S., Long, F., Jhala, U. S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, D., Schutz, G., Yoon, C., Puigserver, P., et al. (2001) · Nature · doi:10.1038/35093131 · Cited by 1,440 · cited 1×
“CREB may also promote gluconeogenesis through increased PGC-1 expression (43).”
BackgroundGuertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415 · cited 1×
“GSK-3 phosphorylation was recently found to be preserved despite complete loss of Akt Ser473 phosphorylation in mouse embryo fibroblasts from rictor knockout animals (49).”
BackgroundPeterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202 · cited 1×
“The mTOR complex 1 (mTORC1) is composed of mTOR, G L, PRAS40, deptor, and raptor and regulates cell growth, whereas the complex 2 (mTORC2) consists of mTOR, G L, protor-1, mSIN1, deptor, and rictor and controls cytoskeleton regulation and cell survival (1,2).”
BackgroundBentzinger, C. F., Romanino, K., Cloëtta, D., Lin, S., Mascarenhas, J. B., Oliveri, F., Xia, J., Casanova, E., Costa, C. F., Brink, M., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.10.002 · Cited by 640
Conkright, M. D., Canettieri, G., Screaton, R., Guzman, E., Miraglia, L., Hogenesch, J. B., & Montminy, M. (2003) · Molecular Cell · doi:10.1016/j.molcel.2003.08.013 · Cited by 602 · cited 10×
“This switch is operated by a complex series of acetylation and deacetylation events that affect stability and activity of both CRTC2 and FoxO1.”
BackgroundInfluentialAdipose triglyceride lipase and the lipolytic catabolism of cellular fat stores.
Zechner, R., Kienesberger, P. C., Haemmerle, G., Zimmermann, R., & Lass, A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800031-jlr200 · Cited by 576
Rhee, J., Inoue, Y., Yoon, J. C., Puigserver, P., Fan, M., Gonzalez, F. J., & Spiegelman, B. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730870100 · Cited by 567
Khamzina, L., Veilleux, A., Bergeron, S., & Marette, A. (2005) · Endocrinology · doi:10.1210/en.2004-0921 · Cited by 562 · cited 2×
“treatment with rapamycin also improves insulin signaling to IRS/PI 3-kinase and maintains activation of Akt in the liver, in agreement with our previous findings in hepatocytes acutely treated with the drug (4).”
BackgroundResultSelf-citationAmino Acid and Insulin Signaling via the mTOR/p70 S6 Kinase Pathway
Tremblay, F., & Marette, A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106703200 · Cited by 542 · cited 4×
“Accordingly, we and others have demonstrated that acute treatment with rapamycin in vitro prevents nutrient-induced insulin resistance by interfering with this negative feedback loop and limiting phosphorylation of IRS-1 on multiple serine residues (3,5,7,27).”
BackgroundMethodInfluentialSelf-citationFoxO1 Regulates Multiple Metabolic Pathways in the Liver
Zhang, W., Patil, S., Chauhan, B., Guo, S., Powell, D. R., Le, J., Klotsas, A., Matika, R., Xiao, X., Franks, R., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600272200 · Cited by 516 · cited 14×
“PGC-1 increases gluconeogenic gene expression at least in part by coactivating transcription by FoxO1 (37), possibly through its ability to target O-GlcNAc transferase for GlcNAcylation of FoxO1 (38).”
BackgroundInfluentialNovel concepts in insulin regulation of hepatic gluconeogenesis
Barthel, A., & Schmoll, D. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00253.2003 · Cited by 515 · cited 8×
“In the refed state, insulin suppresses gluconeogenesis by transcriptional downregulation of PEPCK and G6Pase (31).”
BackgroundInfluentialA fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange
Liu, Y., Dentin, R., Chen, D., Hedrick, S., Ravnskjaer, K., Schenk, S., Milne, J., Meyers, D. J., Cole, P., III, J. Y., et al. (2008) · Nature · doi:10.1038/nature07349 · Cited by 484 · cited 1×
“(44) has demonstrated the existence of a temporal switch from CRTC2 to FoxO1 as a critical inducer of gluconeogenesis during a prolonged fast.”
BackgroundAdipose-Specific Knockout of raptor Results in Lean Mice with Enhanced Mitochondrial Respiration
Polak, P., Cybulski, N., Feige, J. N., Auwerx, J., Rüegg, M. A., & Hall, M. N. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.09.003 · Cited by 480 · cited 2×
“This is consistent with the recent finding that disruption of adipose mTORC1 signaling through raptor knockout increased energy expenditure (16).”
BackgroundResultTremblay, F., Brûlé, S., Hee Um, S., Li, Y., Masuda, K., Roden, M., Sun, X. J., Krebs, M., Polakiewicz, R. D., Thomas, G., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706517104 · Cited by 465 · cited 1×
“Moreover, we recently reported that S6K1 plays a key role in hepatic insulin action through phosphorylation of both Ser1101 and Ser636/639 in hepatic cells and liver of obese insulin-resistant high-fat–fed mice (6).”
BackgroundSelf-citationKim, J. E., & Chen, J. (2004) · Diabetes · doi:10.2337/diabetes.53.11.2748 · Cited by 454 · cited 2×
“This is consistent with studies in cell lines in which chronic rapamycin treatment or small interfering RNA–mediated downregulation of either mTOR, raptor, or S6K1 can have direct effects on adipogenesis and lipid content (17,46,47).”
BackgroundResultInsulin modulates gluconeogenesis by inhibition of the coactivator TORC2
Dentin, R., Liu, Y., Koo, S.-H., Hedrick, S., Vargas, T., Heredia, J., Yates, J., & Montminy, M. (2007) · Nature · doi:10.1038/nature06128 · Cited by 400 · cited 10×
“This switch is operated by a complex series of acetylation and deacetylation events that affect stability and activity of both CRTC2 and FoxO1.”
BackgroundInfluentialInsulin Stimulates Adipogenesis through the Akt-TSC2-mTORC1 Pathway
Zhang, H. H., Huang, J., Düvel, K., Boback, B., Wu, S., Squillace, R. M., Wu, C.-L., & Manning, B. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006189 · Cited by 399 · cited 2×
“mTORC1 and, more recently, raptor have been shown to control adipogenesis (17) through Akt-mediated phosphorylation of tuberous sclerosis complex 2 (18).”
BackgroundTzatsos, A., & Kandror, K. V. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.63-76.2006 · Cited by 399 · cited 1×
“Accordingly, we and others have demonstrated that acute treatment with rapamycin in vitro prevents nutrient-induced insulin resistance by interfering with this negative feedback loop and limiting phosphorylation of IRS-1 on multiple serine residues (3,5,7,27).”
BackgroundPeng, T., Golub, T. R., & Sabatini, D. M. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5575-5584.2002 · Cited by 395 · cited 1×
“Because rapamycin blocks a major nutrientsensing pathway, it has been suggested that it mimics a starvation-like signal even in the presence of nutrients (33) and as such could explain the increase in PGC-1 expression.”
BackgroundMorrisett, J. D., Abdel-Fattah, G., Hoogeveen, R., Mitchell, E., Ballantyne, C. M., Pownall, H. J., Opekun, A. R., Jaffe, J. S., Oppermann, S., & Kahan, B. D. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m100392-jlr200 · Cited by 295 · cited 1×
“Indeed chronic rapamycin administration was found to cause hyperlipidemia and to reduce fat mass, as well as to promote glucose intolerance and a diabeteslike syndrome (8,10,11).”
BackgroundTissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-α
Puigserver, P. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802905 · Cited by 289
Regulation of PGC-1 Promoter Activity by Protein Kinase B and the Forkhead Transcription Factor FKHR
Daitoku, H., Yamagata, K., Matsuzaki, H., Hatta, M., & Fukamizu, A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.642 · Cited by 262 · cited 1×
“Conversely, insulin suppresses gluconeogenesis through Akt-dependent phosphorylation of FoxO1, leading to its nuclear exclusion and degradation (39).”
BackgroundTakano, A., Usui, I., Haruta, T., Kawahara, J., Uno, T., Iwata, M., & Kobayashi, M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.15.5050-5062.2001 · Cited by 251 · cited 1×
“Other studies have shown that long-term activation of the mTORC1/S6K1 pathway also promotes insulin resistance through the proteasomal degradation of IRS-1 (28) and IRS-2 (29).”
BackgroundTeutonico, A., Schena, P. F., & Di Paolo, S. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005050487 · Cited by 239 · cited 1×
“Indeed chronic rapamycin administration was found to cause hyperlipidemia and to reduce fat mass, as well as to promote glucose intolerance and a diabeteslike syndrome (8,10,11).”
BackgroundHousley, M. P., Udeshi, N. D., Rodgers, J. T., Shabanowitz, J., Puigserver, P., Hunt, D. F., & Hart, G. W. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808890200 · Cited by 216 · cited 14×
“PGC-1 increases gluconeogenic gene expression at least in part by coactivating transcription by FoxO1 (37), possibly through its ability to target O-GlcNAc transferase for GlcNAcylation of FoxO1 (38).”
BackgroundInfluentialRachdi, L., Balcazar, N., Osorio-Duque, F., Elghazi, L., Weiss, A., Gould, A., Chang-Chen, K. J., Gambello, M. J., & Bernal-Mizrachi, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803047105 · Cited by 209 · cited 1×
“This is consistent with recent reports that chronic activation of mTOR leads to -cell mass expansion (15,45).”
ResultWeinstock, P. H., Levak-Frank, S., Hudgins, L. C., Radner, H., Friedman, J. M., Zechner, R., & Breslow, J. L. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10261 · Cited by 208 · cited 1×
“tion of the expression of enzymes required for intravascular hydrolysis (LPL), cellular uptake (FAT/CD36 and FATP1), and storage of lipid (PEPCK and lipin), all known to impact adiposity (48), appeared to be counterbalanced by the downregulation of lipolytic (ATGL, MGL) enzyme expression, consistent with the near main…”
BackgroundReue, K., & Brindley, D. N. (2008) · Journal of Lipid Research · doi:10.1194/jlr.r800019-jlr200 · Cited by 196
Aguilar, V., Alliouachene, S., Sotiropoulos, A., Sobering, A., Athea, Y., Djouadi, F., Miraux, S., Thiaudière, E., Foretz, M., Viollet, B., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.006 · Cited by 183
Tremblay, F., Gagnon, A., Veilleux, A., Sorisky, A., & Marette, A. (2005) · Endocrinology · doi:10.1210/en.2004-0777 · Cited by 175 · cited 1×
“Accordingly, we and others have demonstrated that acute treatment with rapamycin in vitro prevents nutrient-induced insulin resistance by interfering with this negative feedback loop and limiting phosphorylation of IRS-1 on multiple serine residues (3,5,7,27).”
BackgroundSelf-citationmTOR complex 2 in adipose tissue negatively controls whole-body growth
Cybulski, N., Polak, P., Auwerx, J., Rüegg, M. A., & Hall, M. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811321106 · Cited by 174 · cited 1×
“Our conclusion that mTORC2 inhibition cannot account for the reduction of adiposity is also supported by recent studies in mice with adipose tissue–specific disruption of rictor and mTORC2 signaling, which failed to reduce adipogenesis or fat mass in chow-fed animals (50).”
ResultBriaud, I., Dickson, L. M., Lingohr, M. K., McCuaig, J. F., Lawrence, J. C., & Rhodes, C. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m412179200 · Cited by 158
Festuccia, W. T., Laplante, M., Berthiaume, M., Gélinas, Y., & Deshaies, Y. (2006) · Diabetologia · doi:10.1007/s00125-006-0336-y · Cited by 143 · cited 11×
“1, and adipose tissue was sampled and processed as described in the RESEARCH DESIGN AND METHODS section for determinations of LPL, FATP1, FAT/CD36, Lipin1, PEPCK, MGL, HSL, ATGL, PPAR 1, and PPAR 2 mRNA expression.”
BackgroundInfluentialSelf-citationManagement of Side Effects of Sirolimus Therapy
Stallone, G., Infante, B., Grandaliano, G., & Gesualdo, L. (2009) · Transplantation · doi:10.1097/tp.0b013e3181a05b7a · Cited by 131 · cited 1×
“However, somewhat paradoxically it appears that a significant side effect of chronic inhibition of mTORC1/S6K1 signaling by rapamycin treatment is deranged lipid and glucose metabolism (9).”
BackgroundLaplante, M., Festuccia, W. T., Soucy, G., Gélinas, Y., Lalonde, J., Berger, J. P., & Deshaies, Y. (2006) · Diabetes · doi:10.2337/db06-0551 · Cited by 119 · cited 12×
“Retroperitoneal adipose tissue expression of lipoprotein lipase (LPL), which catalyzes the hydrolysis of lipoprotein-bound triglycerides supplying fatty acids and glycerol for adipose depot uptake (20), along with the fatty acid transporters (FATP1 and FAT/ CD36) were all downregulated by rapamycin treatment (Fig.”
BackgroundInfluentialSelf-citationGiraud, J., Leshan, R. L., Lee, Y.-H., & White, M. F. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308631200 · Cited by 104 · cited 1×
“Accordingly, we and others have demonstrated that acute treatment with rapamycin in vitro prevents nutrient-induced insulin resistance by interfering with this negative feedback loop and limiting phosphorylation of IRS-1 on multiple serine residues (3,5,7,27).”
BackgroundHamada, S., Hara, K., Hamada, T., Yasuda, H., Moriyama, H., Nakayama, R., Nagata, M., & Yokono, K. (2009) · Diabetes · doi:10.2337/db08-0519 · Cited by 97
Veilleux, A., Houde, V. P., Bellmann, K., & Marette, A. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0328 · Cited by 94
Self-citationBerthiaume, M., Laplante, M., Festuccia, W. T., Gélinas, Y., Poulin, S., Lalonde, J., Joanisse, D. R., Thieringer, R., & Deshaies, Y. (2007) · Endocrinology · doi:10.1210/en.2006-1199 · Cited by 94
Self-citationFestuccia, W. T., Blanchard, P.-G., Turcotte, V., Laplante, M., Sarıahmetoğlu, M., Brindley, D. N., & Deshaies, Y. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m800620-jlr200 · Cited by 85
Self-citationGlyceroneogenesis comes of age
BEALE, E. G., Hammer, R. E., Antoine, B., & Forest, C. D. (2002) · The FASEB Journal · doi:10.1096/fj.02-0407rev · Cited by 63 · cited 1×
“In addition, phosphoenolpyruvate carboxykinase (PEPCK), which generates the glycerol 3-phosphate backbone for fatty acid esterification (21), and lipin 1, an important enzyme involved in triglyceride synthesis (22), were also significantly reduced by rapamycin treatment.”
BackgroundEl‐Chaâr, D., Gagnon, A.-M., & Sorisky, A. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802554 · Cited by 60 · cited 2×
“This is consistent with studies in cell lines in which chronic rapamycin treatment or small interfering RNA–mediated downregulation of either mTOR, raptor, or S6K1 can have direct effects on adipogenesis and lipid content (17,46,47).”
BackgroundResultXu, E., Dubois, M.-J., Leung, N., Charbonneau, A., Turbide, C., Avramoglu, R. K., DeMarte, L., Elchebly, M., Streichert, T., Levy, E. H., et al. (2009) · Endocrinology · doi:10.1210/en.2008-1439 · Cited by 52 · cited 1×
“Liver nuclear extracts were prepared as previously described (12) and submitted to immunoblotting as described above.”
MethodSelf-citationNonimmunosuppressive effects of mammalian target of rapamycin inhibitors
Cruzado, J. M. (2007) · Transplantation Reviews · doi:10.1016/j.trre.2007.09.003 · Cited by 36 · cited 2×
“In fact, rapamycin is already used in the clinic as an effective immunosuppressant in human transplant recipients to prevent graft rejection (8).”
Background
Research works printed but not linked: 1
- Hamada, Upregulation of the mTOR complex 1 pathway by Rheb in pancreatic β cells leads to increased β cell mass and prevention of hyperglycemia, Diabetes
Cited by
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
“Rapamycin reduces adipose tissue size and b-cell mass and function and causes hyperlipidemia, severe insulin resistance, and glucose intolerance and promotes hepatic gluconeogenesis (Aggarwal et al., 2006; Cunningham et al., 2007; Fraenkel et al., 2008; Houde et al., 2010) (Figure 5A).”
Rapamycin: one drug, many effects
Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287
Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., et al. (2012) · Science · doi:10.1126/science.1215135 · Cited by 1,199
Henske, E. P., Jóźwiak, S., Kingswood, J. C., Sampson, J. R., & Thiele, E. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.35 · Cited by 831
Miller, R. A., Harrison, D. E., Astle, C. M., Fernandez, E., Flurkey, K., Han, M., Javors, M. A., Li, X., Nadon, N. L., Nelson, J. F., et al. (2014) · Aging Cell · doi:10.1111/acel.12194 · Cited by 621
“Chronic injection of rapamycin also causes hepatic insulin resistance in young C57BL/6 mice and SpragueDawley rats (Houde et al., 2010; Lamming et al., 2012).”
Background
Metadata
- Authors
- Houde, V. P., Brûlé, S., Festuccia, W. T., Blanchard, P.-G., Bellmann, K., Deshaies, Y., & Marette, A.
- Affiliations
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Corresponding author
- Marette, André
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-03-18
- Volume
- 59
- Issue
- 6
- Pages
- 1338-1348
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2874694
- OpenAlex
- W2153442288
- Cited by
- 456
- References
- 51
- Citations by year
- 2026: 12 · 2025: 25 · 2024: 14 · 2023: 25 · 2022: 20 · 2021: 30 · 2020: 25 · 2019: 26 · 2018: 33 · 2017: 37 · 2016: 35 · 2015: 42 · 2014: 47 · 2013: 32 · 2012: 30
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval
- Canadian Institutes of Health Research (144336)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- hepatic gluconeogenesis, impaired glucose tolerance, hyperlipidemia, insulin resistance, PGC-1α, FOXO1, CRTC2, CREB, PI3K/Akt signaling, phosphoenolpyruvate carboxykinase, glucose-6-phosphatase, adiposity
- MeSH terms
- Adipose Tissue, Animals, Blood Glucose, C-Peptide, Fatty Acids, Nonesterified, Glucagon, Hyperlipidemias, Immunosuppressive Agents, Insulin, Liver, Male, Pyruvates, RNA, Triglycerides, Down-Regulation, Polymerase Chain Reaction, Rats, Sprague-Dawley, Adipocytes, Glucose Intolerance, Muscle, Skeletal, Sirolimus, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.